This is a preview of subscription content, log in via an institution to check access.
Notes
Standard And New Antiepileptic Drug
Reference
Marson A, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet : 10 Apr 2021. Available from: URL: https://doi.org/10.1016/S0140-6736(21)00246-4
Rights and permissions
About this article
Cite this article
Levetiracetam for newly diagnosed generalised or unclassified epilepsy: fewer QALYs, higher costs than valproate. PharmacoEcon Outcomes News 877, 12 (2021). https://doi.org/10.1007/s40274-021-7661-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7661-8